300 related articles for article (PubMed ID: 23074286)
1. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer.
Majid S; Dar AA; Saini S; Arora S; Shahryari V; Zaman MS; Chang I; Yamamura S; Tanaka Y; Deng G; Dahiya R
Cancer Res; 2012 Dec; 72(24):6435-46. PubMed ID: 23074286
[TBL] [Abstract][Full Text] [Related]
2. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways.
Majid S; Dar AA; Saini S; Shahryari V; Arora S; Zaman MS; Chang I; Yamamura S; Tanaka Y; Chiyomaru T; Deng G; Dahiya R
Clin Cancer Res; 2013 Jan; 19(1):73-84. PubMed ID: 23147995
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-23b functions as a tumor suppressor by regulating Zeb1 in bladder cancer.
Majid S; Dar AA; Saini S; Deng G; Chang I; Greene K; Tanaka Y; Dahiya R; Yamamura S
PLoS One; 2013; 8(7):e67686. PubMed ID: 23844063
[TBL] [Abstract][Full Text] [Related]
4. The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related.
Rice MA; Ishteiwy RA; Magani F; Udayakumar T; Reiner T; Yates TJ; Miller P; Perez-Stable C; Rai P; Verdun R; Dykxhoorn DM; Burnstein KL
Oncogene; 2016 Sep; 35(36):4752-61. PubMed ID: 26898757
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.
Huang K; Chen J; Yang MS; Tang YJ; Pan F
Cancer Biomark; 2017; 18(3):231-239. PubMed ID: 28085008
[TBL] [Abstract][Full Text] [Related]
6. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.
Rashed MH; Kanlikilicer P; Rodriguez-Aguayo C; Pichler M; Bayraktar R; Bayraktar E; Ivan C; Filant J; Silva A; Aslan B; Denizli M; Mitra R; Ozpolat B; Calin GA; Sood AK; Abd-Ellah MF; Helal GK; Berestein GL
Oncotarget; 2017 Mar; 8(12):20145-20164. PubMed ID: 28423620
[TBL] [Abstract][Full Text] [Related]
7. microRNA-1246 Is an Exosomal Biomarker for Aggressive Prostate Cancer.
Bhagirath D; Yang TL; Bucay N; Sekhon K; Majid S; Shahryari V; Dahiya R; Tanaka Y; Saini S
Cancer Res; 2018 Apr; 78(7):1833-1844. PubMed ID: 29437039
[TBL] [Abstract][Full Text] [Related]
8. The other face of miR-17-92a cluster, exhibiting tumor suppressor effects in prostate cancer.
Ottman R; Levy J; Grizzle WE; Chakrabarti R
Oncotarget; 2016 Nov; 7(45):73739-73753. PubMed ID: 27650539
[TBL] [Abstract][Full Text] [Related]
9. The reciprocal regulation loop of Notch2 pathway and miR-23b in controlling gastric carcinogenesis.
Huang TT; Ping YH; Wang AM; Ke CC; Fang WL; Huang KH; Lee HC; Chi CW; Yeh TS
Oncotarget; 2015 Jul; 6(20):18012-26. PubMed ID: 26041881
[TBL] [Abstract][Full Text] [Related]
10. Nc886 is epigenetically repressed in prostate cancer and acts as a tumor suppressor through the inhibition of cell growth.
Fort RS; Mathó C; Geraldo MV; Ottati MC; Yamashita AS; Saito KC; Leite KRM; Méndez M; Maedo N; Méndez L; Garat B; Kimura ET; Sotelo-Silveira JR; Duhagon MA
BMC Cancer; 2018 Feb; 18(1):127. PubMed ID: 29394925
[TBL] [Abstract][Full Text] [Related]
11. MiR-301a regulates E-cadherin expression and is predictive of prostate cancer recurrence.
Nam RK; Benatar T; Wallis CJ; Amemiya Y; Yang W; Garbens A; Naeim M; Sherman C; Sugar L; Seth A
Prostate; 2016 Jul; 76(10):869-84. PubMed ID: 26990571
[TBL] [Abstract][Full Text] [Related]
12. A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition.
Bucay N; Bhagirath D; Sekhon K; Yang T; Fukuhara S; Majid S; Shahryari V; Tabatabai Z; Greene KL; Hashimoto Y; Shiina M; Yamamura S; Tanaka Y; Deng G; Dahiya R; Saini S
Cell Death Differ; 2017 Jul; 24(7):1263-1274. PubMed ID: 28498363
[TBL] [Abstract][Full Text] [Related]
13. microRNA-23b suppresses epithelial-mesenchymal transition (EMT) and metastasis in hepatocellular carcinoma via targeting Pyk2.
Cao J; Liu J; Long J; Fu J; Huang L; Li J; Liu C; Zhang X; Yan Y
Biomed Pharmacother; 2017 May; 89():642-650. PubMed ID: 28262617
[TBL] [Abstract][Full Text] [Related]
14. The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells.
Ishteiwy RA; Ward TM; Dykxhoorn DM; Burnstein KL
PLoS One; 2012; 7(12):e52106. PubMed ID: 23300597
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-23b suppresses cervical cancer biological progression by directly targeting six1 and affecting epithelial-to-mesenchymal transition and AKT/mTOR signaling pathway.
Li YM; Li XJ; Yang HL; Zhang YB; Li JC
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4688-4697. PubMed ID: 31210295
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis.
Lu C; Shan Z; Hong J; Yang L
Int J Oncol; 2017 Jul; 51(1):235-244. PubMed ID: 28534966
[TBL] [Abstract][Full Text] [Related]
17. MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches.
Aghaee-Bakhtiari SH; Arefian E; Naderi M; Noorbakhsh F; Nodouzi V; Asgari M; Fard-Esfahani P; Mahdian R; Soleimani M
Tumour Biol; 2015 Jun; 36(6):4203-12. PubMed ID: 25604141
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-539 functions as a tumour suppressor in prostate cancer via the TGF-β/Smad4 signalling pathway by down-regulating DLX1.
Sun B; Fan Y; Yang A; Liang L; Cao J
J Cell Mol Med; 2019 Sep; 23(9):5934-5948. PubMed ID: 31298493
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer.
Hudson RS; Yi M; Esposito D; Watkins SK; Hurwitz AA; Yfantis HG; Lee DH; Borin JF; Naslund MJ; Alexander RB; Dorsey TH; Stephens RM; Croce CM; Ambs S
Nucleic Acids Res; 2012 Apr; 40(8):3689-703. PubMed ID: 22210864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
